Pascual-Camps Isabel, Hernández-Martínez Pablo, Monje-Fernández Laura, Dolz-Marco Rosa, Gallego-Pinazo Roberto, Wu Lihteh, Arévalo J Fernando, Díaz-Llopis Manuel
Department of Ophthalmology, University and Polytechnic Hospital La Fe, Av. Fernando Abril Martorell, n° 106, Valencia, 46026, Spain.
Department of Ophthalmology, University Hospital Complex, Alto de Nava s/n, Leon, 24071, Spain.
J Ophthalmic Inflamm Infect. 2014 Oct 15;4:26. doi: 10.1186/s12348-014-0026-8. eCollection 2014.
Tumor necrosis factor alpha (TNF-?) is an important pro-inflammatory cytokine associated with a variety of ocular diseases. The currently available TNF-? inhibitors are etanercept, infliximab, adalimumab, golimumab, and certolizumab. Experimental and clinical studies on the intravitreal use of these agents have been reported with etanercept, infliximab, and adalimumab: etanercept has shown limited efficacy in scarce reports; infliximab has been associated with local safety concerns but appears to benefit certain cases; adalimumab has shown no efficacy in cases of age-related macular degeneration (AMD) or diabetic macular edema (DME), but the combination with bevacizumab may be effective in refractory cases of macular diseases. Further preclinical and clinical studies are warranted in order to be able to obtain a more robust conclusion on the use of intravitreal TNF-? inhibitors.
肿瘤坏死因子α（TNF-α）是一种与多种眼部疾病相关的重要促炎细胞因子。目前可用的TNF-α抑制剂有依那西普、英夫利昔单抗、阿达木单抗、戈利木单抗和赛妥珠单抗。关于玻璃体内使用这些药物的实验和临床研究已有依那西普、英夫利昔单抗和阿达木单抗的报道：依那西普在少数报道中显示疗效有限；英夫利昔单抗存在局部安全性问题，但似乎对某些病例有益；阿达木单抗在年龄相关性黄斑变性（AMD）或糖尿病性黄斑水肿（DME）病例中未显示疗效，但与贝伐单抗联合使用可能对难治性黄斑疾病病例有效。为了能够就玻璃体内使用TNF-α抑制剂得出更可靠的结论，有必要进行进一步的临床前和临床研究。
